De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Clearbridge Health Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jeremy Yee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.4yrs
Eigendom CEO	4.5%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	6.9yrs

Recente managementupdates

Recent updates

CEO

Jeremy Yee (54 yo)

7.4yrs

Tenure

Mr. Pinh Yee, also known as Jeremy, BA (Econ), B.Com. Pr Acct, M. Com., serves as Executive Director since 15 May 2017 and Chief Executive Officer of Clearbridge Health Ltd.Mr. Yee served as Chief Executi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pinh Yee	CEO & Executive Director	no data	geen gegevens	4.46% SGD 249.0k
Wei Chee Tan	Financial Controller	2yrs	geen gegevens	geen gegevens
Kia Wei Hoo	Chief Business Officer	7.5yrs	geen gegevens	0.96% SGD 53.6k
Moi Heyang Lin	Joint Company Secretary	less than a year	geen gegevens	geen gegevens
Pei Chan Tang	Joint Company Secretary	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

Ervaren management: Het managementteam van 1H3 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Pinh Yee	CEO & Executive Director	7.4yrs	geen gegevens	4.46% SGD 249.0k
Johnson Chen	Non-Executive Non-Independent Chairman	14.8yrs	geen gegevens	17.45% SGD 973.0k
Khee Chee Soo	Member of Medical Advisory Board	6.2yrs	geen gegevens	geen gegevens
Mark Benedict Ryan	Independent Director	6.9yrs	geen gegevens	0.34% SGD 18.9k
How Soon Mah	Independent Director	6.6yrs	geen gegevens	geen gegevens
Andrew John Lord	Lead Independent Director	6.9yrs	geen gegevens	geen gegevens

6.9yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1H3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).

Clearbridge Health Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Clearbridge Health Limited, Annual General Meeting, Apr 29, 2024

Clearbridge Health Limited Announces Resignation of Liau Yen San, Jonathan as Chief Operating Officer

Clearbridge Health Limited Announces Board Changes

Clearbridge Health Limited, Annual General Meeting, Jun 28, 2023

Clearbridge Health Limited Announces Retirement of Tan Soon Liang (Chen Shunliang) as Independent Director

Insufficient new directors

Recent updates

New major risk - Financial position

Clearbridge Health Limited, Annual General Meeting, Apr 29, 2024

Full year 2023 earnings released: S$0.052 loss per share (vs S$0.02 loss in FY 2022)

Clearbridge Health Limited Announces Resignation of Liau Yen San, Jonathan as Chief Operating Officer

Clearbridge Health Limited to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Share price stability

New minor risk - Share price stability

New major risk - Financial position

First half 2023 earnings released: S$0.002 loss per share (vs S$0.014 loss in 1H 2022)

Clearbridge Health Limited Announces Board Changes

Clearbridge Health Limited, Annual General Meeting, Jun 28, 2023

Clearbridge Health Limited Announces Retirement of Tan Soon Liang (Chen Shunliang) as Independent Director

Full year 2022 earnings released: S$0.016 loss per share (vs S$0.032 loss in FY 2021)

Insufficient new directors

PT Lunadorii Utama Indonesia acquired SAM Laboratory Private Limited from Clearbridge Health Limited (Catalist:1H3) for SGD 8.6 million.

Clearbridge Health Limited Announces Resignation of Fexlicia Lee Pei Yue as Financial Controller

First half 2022 earnings released: S$0.013 loss per share (vs S$0.014 loss in 1H 2021)

Clearbridge Health Limited Announces Change of Company Secretaries, Effective June 24, 2022

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Clearbridge Health Limited, Annual General Meeting, Apr 26, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Clearbridge Health Limited Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Insufficient new directors

Revenue and earnings miss expectations

Full year 2020 earnings released

Clearbridge Health Limited Announces Executive Changes

Price target lowered to S$0.26

First half earnings released

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd